09:29 AM EDT, 09/16/2024 (MT Newswires) -- Exact Sciences ( EXAS ) was advancing in Monday's premarket activity, with shares rising over 4%, after the company presented performance data it said showed its blood-based screening test for colorectal cancer had an 88.3% sensitivity for the disease and 31.2% for advanced precancerous lesions.

Both tests had a specificity of 90.1% for negative samples confirmed by colonoscopy, the company said during an oral presentation at the European Society for Medical Oncology Congress now underway in Barcelona, Spain.

Price: 68.39, Change: +2.85, Percent Change: +4.35